Overview

* CervoMed Q3 2025 net loss of $7.7 mln misses analyst expectations

* Cash position decreased to $27.3 mln as of September 30, 2025

Outlook

* CervoMed plans to initiate a global pivotal Phase 3 trial in DLB in H2 2026

* Company expects initial biomarker data from Phase 2a FTD trial in 2026

* CervoMed ( CRVO ) aligned with FDA on Phase 3 trial design for neflamapimod in DLB

Result Drivers

* CASH POSITION -

As of September 30, CervoMed ( CRVO ) had 27.3 mln in cash, cash equivalents, and marketable securities vs $38.9 mln as of December 31

* OPERATING PLAN - CervoMed believes its cash will fund operations into Q3 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Miss -$7.70 -$6.33

Income mln mln (5

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for CervoMed Inc ( CRVO ) is $20.00, about 65.4% above its November 7 closing price of $6.92

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)